## In the Claims

Applicants hereby submit a new complete claims set with insertions and deletions indicated by underlining and strikeouts, respectively.

Please amend claims 1 and 19 as follows.

1. (currently amended) A pharmaceutical composition comprising:

a pharmaceutical composition for administration to a subject, comprising a polymer of less than 50 kilodaltons having at least two repeating charge motifs, wherein the repeating charge motif is composed of a positively charged free amino moiety and a negative charge, wherein the positively charged free amino moieties of the at least two repeating charge motifs are separated by an intervening sequence of at least 32 A, and wherein the intervening sequence is neutral, and

a pharmaceutically acceptable carrier.

- 2. (original) The composition of claim 1, wherein the polymer has non-repeating units.
- 3. (original) The composition of claim 1, wherein the polymer has repeating units.
- 4. (original) The composition of claim 3, wherein the polymer has identical repeating units.
- 5. (original) The composition of claim 3, wherein the polymer has non-identical repeating units.
- 6. (original) The composition of claim 1, wherein the polymer is a mixed polymer.
- 7. (original) The composition of claim 6, wherein the mixed polymer is a peptide-nucleic acid.

8. (original) The composition of claim 1, wherein the polymer has at least 10 repeating charge motifs.

- 9. (original) The composition of claim 1, wherein the polymer has at least 15 repeating charge motifs.
- 10. (original) The composition of claim 1, wherein the polymer has at least 20 repeating charge motifs.
- 11. (original) The composition of claim 1, wherein the positively charged free amino moieties of the at least two repeating charge motifs are separated by a distance of at least 115 A.
- 12. (original) The composition of claim 1, wherein the positively charged free amino moieties of the at least two repeating charge motifs are separated by a distance of at least 155 Å.
- 13. (original) The composition of claim 1, wherein the positively charged free amino moieties of the at least two repeating charge motifs are separated by a distance of at least 200 Å.
- 14. (original) The composition of claim 1, wherein the polymer is a synthetic polypeptide.
- 15. (original) The composition of claim 1, wherein the polymer is a non-native polypeptide.
- 16. (original) The composition of claim 1, wherein the polymer is a polypeptide having at least one modified amino acid.
- 17. (original) The composition of claim 1, wherein the polymer is a polypeptide having at least ten modified amino acids.

18. (original) The composition of claim 1, wherein the polymer is a polypeptide having a positive to negative charge ratio of 1:1.

- 19. (currently amended) A pharmaceutical composition comprising:

  a pharmaceutical composition for administration to a subject, comprising a polypeptide of less than 50 kilodaltons having at least two repeating charge motifs, wherein the repeating charge motif is composed of a positively charged free amino moiety and a negative charge, wherein the positively charged free amino moieties of the at least two repeating charge motifs are separated by a distance of at least 8 amino acids, and a pharmaceutically acceptable carrier.
- 20-36. (canceled)
- 37. (withdrawn)
- 38-60. (canceled)
- 61. (withdrawn)
- 62. (canceled)
- 63. (withdrawn)
- 64. (canceled)
- 65. (withdrawn)
- 66. (canceled)

09/540,024 67. (withdrawn) 68.-100. (canceled) 101. (withdrawn) 102. (canceled) 103-104. (withdrawn) 105. (canceled) 106. (withdrawn) 107. (canceled) 108. (withdrawn) 109-110. (canceled) 111. (withdrawn) 112-126. (canceled)

127. (withdrawn)

128-137. (canceled)

138. (withdrawn)

- 139-146. (canceled)
- 147. (previously added) The composition of claim 19, wherein the polypeptide has non-repeating units.
- 148. (previously added) The composition of claim 19, wherein the polypeptide has repeating units.
- 149. (previously added) The composition of claim 19, wherein the polypeptide has at least 10 repeating charge motifs.
- 150. (previously added) The composition of claim 19, wherein the polypeptide has at least 15 repeating charge motifs.
- 151. (previously added) The composition of claim 19, wherein the polypeptide has at least 20 repeating charge motifs.
- 152. (previously added) The composition of claim 19, wherein the positive and negative charges of the repeating charge motifs are separated by at least one neutral amino acid.
- 153. (previously added) The composition of claim 19, wherein the positive and negative charges of the repeating charge motifs are separated by at least five neutral amino acids.
- 154. (previously added) The composition of claim 19, wherein the positive and negative charges of the repeating charge motifs are on adjacent amino acids and are not separated by any neutral amino acids.
- 155. (previously added) The composition of claim 19, wherein the positively charged free amino moieties of the at least two repeating charge motifs are separated by a distance of at least 27 amino acids.

156. (previously added) The composition of claim 19, wherein the positively charged free amino moieties of the at least two repeating charge motifs are separated by a distance of at least 37 amino acids.

- 157. (previously added) The composition of claim 19, wherein the positively charged free amino moieties of the at least two repeating charge motifs are separated by a distance of at least 47 amino acids.
- 158. (previously added) The composition of claim 19, wherein the polypeptide is a synthetic polypeptide.
- 159. (previously added) The composition of claim 19, wherein the polypeptide is a non-native polypeptide.
- 160. (previously added) The composition of claim 19, wherein the polypeptide has at least one modified amino acid.
- 161. (previously added) The composition of claim 19, wherein the polypeptide has at least ten modified amino acids.
- 162. (previously added) The composition of claim 19, wherein the polypeptide has a positive to negative charge ratio of 1:1.
- 163. (previously added) The composition of claim 19, wherein the amino acids separating the charged repeats are neutral amino acids.